Keenova Publishes Real-World Data on Acthar Gel for Severe Autoimmune Diseases
Event summary
- Keenova Therapeutics published a manuscript in the Journal of Comparative Effectiveness Research on July 13, 2026, detailing real-world clinical data on Acthar Gel for rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis/polymyositis (DM/PM).
- The retrospective study evaluated patient characteristics, treatment patterns, and physician-assessed outcomes in treatment-refractory cases.
- Acthar Gel is indicated for adjunctive therapy in RA, SLE, and DM/PM, among other conditions.
The big picture
Keenova's publication of real-world data for Acthar Gel underscores the growing importance of retrospective clinical studies in validating treatments for rare and severe autoimmune conditions. The findings could bolster Acthar Gel's position as a therapeutic option for patients who have not responded to prior therapies, particularly in diseases like RA, SLE, and DM/PM where treatment options remain limited.
What we're watching
- Clinical Adoption
- How the real-world evidence will influence physician prescribing patterns for Acthar Gel in treatment-refractory autoimmune cases.
- Regulatory Impact
- Whether the data could support expanded indications or label updates for Acthar Gel in RA, SLE, and DM/PM.
- Competitive Positioning
- The pace at which Keenova can leverage this evidence to differentiate Acthar Gel from emerging therapies in autoimmune disease treatment.